Otsuka Pharmaceutical Development & Commercialization recalls

Otsuka Pharmaceutical Development & Commercialization has 2 recalls on record with the FDA and USDA, the earliest in 2018 and the latest reported on 10 Oct 2018. The most frequent reason is labeling errors.

Total recalls2since 2018

Last 12 months0reported

Class I00% of total

Ongoing0latest 10 Oct 2018

Recalls per month, last 24 months

click a bar for that month

0Oct '24 0 0 0Jan '25 0 0 0Apr 0 0 0Jul 0 0 0Oct 0 0 0Jan '26 0 0 0Apr 0 0 0Jul 0 0

Severity split

Class I 0 0%Class II 0 0%Class III 2 100%

Why otsuka pharmaceutical development & commercialization is recalled

Labeling Errors2100%

Product types

Injectable & IV Drugs2100%

By year

20182100%

All otsuka pharmaceutical development & commercialization recalls, newest first

2 total

Reported	Class	Recall	Company	Reason	Where
10 Oct 2018Drug	CLASS III	treatNOW Abilify (aripiprazole) and Abilify Maintena recalled	Otsuka Pharmaceutical Development & Commercialization	Labeling Errors	Nationwide
10 Oct 2018Drug	CLASS III	treatNOW Abilify (aripiprazole) / Abilify Maintena 400-mg recalled	Otsuka Pharmaceutical Development & Commercialization	Labeling Errors	Nationwide

About this list

Records come from FDA enforcement reports and USDA FSIS notices, grouped by normalised name. A company operating under several names may appear more than once.